These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29382024)

  • 21. A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential Hypertension.
    Lee HY; Kim KI; Ihm SH; Rhee MY; Sohn IS; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
    Clin Ther; 2021 Oct; 43(10):1746-1756. PubMed ID: 34503866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of age on the pharmacokinetics of fimasartan (BR-A-657).
    Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Cho JY; Yu KS; Yoon YR
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1337-44. PubMed ID: 21950382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia.
    Rhee MY; Ahn T; Chang K; Chae SC; Yang TH; Shim WJ; Kang TS; Ryu JK; Nah DY; Park TH; Chae IH; Park SW; Lee HY; Tahk SJ; Yoon YW; Shim CY; Shin DG; Seo HS; Lee SY; Kim DI; Kwan J; Joo SJ; Jeong MH; Jeong JO; Sung KC; Kim SY; Kim SH; Chun KJ; Oh DJ
    BMC Pharmacol Toxicol; 2017 Jan; 18(1):2. PubMed ID: 28057081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives.
    Angeli F; Verdecchia P; Trapasso M; Pane M; Signorotti S; Reboldi G
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):533-541. PubMed ID: 29676941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
    Lee HY; Kim YJ; Ahn T; Youn HJ; Chull Chae S; Seog Seo H; Kim KS; Rhee MY; Choi DJ; Kim JJ; Chun KJ; Yoo BS; Park JS; Oh SK; Kim DS; Kwan J; Ahn Y; Bae Park J; Jeong JO; Hyon MS; Cho EJ; Han KR; Kim DI; Joo SJ; Shin JH; Sung KC; Jeon ES
    Clin Ther; 2015 Nov; 37(11):2581-2596.e3. PubMed ID: 25850881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension.
    Lee HY; Kim CH; Song JK; Chae SC; Jeong MH; Kim DS; Oh BH
    Korean J Intern Med; 2017 Nov; 32(6):1025-1036. PubMed ID: 29032666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers.
    Yi S; Kim JW; Kim TE; Kim J; Jun YK; Choi J; Yoon SH; Cho JY; Song SH; Shin SG; Jang IJ; Yu KS
    Int J Clin Pharmacol Ther; 2011 May; 49(5):321-7. PubMed ID: 21543035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan.
    Kim CO; Lee HW; Oh ES; Seong SJ; Kim DY; Lee J; Ahn SH; Yoon YR; Cho CM; Park MS
    J Cardiovasc Pharmacol; 2013 Dec; 62(6):524-9. PubMed ID: 24084213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fimasartan reduces neointimal formation and inflammation after carotid arterial injury in apolipoprotein E knockout mice.
    Kim JH; Lim IR; Joo HJ; Park CY; Choi SC; Jeong HS; Hong SJ
    Mol Med; 2019 Jul; 25(1):33. PubMed ID: 31307370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy.
    Kim KI; Shin MS; Ihm SH; Youn HJ; Sung KC; Chae SC; Nam CW; Seo HS; Park SM; Rhee MY; Kim MH; Cha KS; Kim YJ; Kim JJ; Chun KJ; Yoo BS; Park S; Shin ES; Kim DS; Il Kim D; Kim KH; Joo SJ; Jeong JO; Shin J; Kim CH
    Clin Ther; 2016 Oct; 38(10):2159-2170. PubMed ID: 27502326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fimasartan.
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):249-52. PubMed ID: 21740078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension.
    Shin MS; Kang DR; Kim C; Cho EJ; Sung KC; Kang SM; Kim DS; Joo SJ; Lee SH; Hwang KK; Park JB
    Drug Des Devel Ther; 2016; 10():1573-80. PubMed ID: 27217724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Could irbesartan trigger autoimmune cholestatic hepatitis?
    Annicchiarico BE; Siciliano M
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):247-8. PubMed ID: 15674105
    [No Abstract]   [Full Text] [Related]  

  • 34. Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia
.
    Katsube Y; Hira D; Tsujimoto M; Koide H; Minegaki T; Ikeda Y; Morita SY; Nishiguchi K; Terada T
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):328-336. PubMed ID: 29792394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3.
    Jeong ES; Kim YW; Kim HJ; Shin HJ; Shin JG; Kim KH; Chi YH; Paik SH; Kim DH
    Xenobiotica; 2015 Jan; 45(1):10-8. PubMed ID: 25034008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Irbesartan-induced acute hepatitis].
    Foruny Olcina JR; Moreira Vicente VF; Gómez García M; Morell Hita JL
    Gastroenterol Hepatol; 2004 Feb; 27(2):71-2. PubMed ID: 14733885
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacological Profiles of a Highly Potent and Long-Acting Angiotensin II Receptor Antagonist, Fimasartan, in Rats and Dogs after Oral Administration.
    Paik SH; Chi YH; Lee JH; Han HS; Lee KT
    Biol Pharm Bull; 2017; 40(7):992-1001. PubMed ID: 28674263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19.
    Soleimani A; Kazemian S; Karbalai Saleh S; Aminorroaya A; Shajari Z; Hadadi A; Talebpour M; Sadeghian H; Payandemehr P; Sotoodehnia M; Bahreini M; Najmeddin F; Heidarzadeh A; Zivari E; Ashraf H
    Am J Hypertens; 2020 Dec; 33(12):1102-1111. PubMed ID: 32920644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.